PARKINSON’s DISEASE
& L-DOPA INDUCED DYSKINESIA

Several movement alterations correlate with modifications to EEG activities.
In Parkinson’s disease, specific antikinetic and prokinetic oscillatory activities (beta and gamma) are prominent. These activities can therefore be used as surrogate translational biomarkers for Drug Discovery.

BetaPark™
Strong Biomarker for Parkinson’s Disease

  • Pharmacosensitive
  • Expressed in PD patients
  • Incredibly stable over time
  • Objective, non tremor related
  • Exclusively revealed by Cue® and EEG​

Clinical observations describe a pathological activity in the 30Hz band (Beta) in parkinsonian patients.
This Beta activity drops with movement initiation.
The unilateral 6-OHDA lesioned rat is a well known model of Parkinson’s disease.

Cue® reveals a specific oscillation (BetaPark) in the 6-OHDA rat motor cortex as found in PD patients.

The BetaPark™ biomarker can be modulated by a pharmacology of reference (Dopamine agonists).
You can assess the pharmacodynamic effects of your compound on BetaPark™ and objectively evaluate how it compares to reference drugs.

Meet BetaPark™
in 4 Steps

GammaPark™
Stong Biomarker for Parkinson’s Disease

  • Pharmacosensitive
  • Expressed in PD patients treated by L-DOPA (levodopa)
  • Objective, non tremor related
  • Exclusively revealed by Cue® and EEG

L-DOPA induced dyskinesia (LID)

Levodopa (L-DOPA) is metabolized into Dopamine.
It is to date the gold strandard for treating PD patients.
Chronic L-DOPA exposure generates several side-effects such as motor complications (L-DOPA Induced Dyskinesia or LID).
L-DOPA treatment stops BetaPark™ transiently but enhances GammaPark™ at the same time.

​GammaPark™ is Pharmacosensitive
Compare. Conclude.

  • GammaPark™ is enhanced by administration of dopamine agonists.
  • Chronic expression of GammaPark™ mirrors patient LID condition.
  • Targeting GammaPark™ is a solid strategy to objectively assess your compound efficacy on LID.
  • GammaPark™ modulation can be used to compare different drugs effects over time.

Time course of GammaPark™ activity when modulated by different dopamine agonists.​
This Time-frequency map shows how GammaPark™ is enhanced by an acute administration of a dopamine agonist in the 6-OHDA Rat.
GammaPark™ remains stable over a time period of 4 hour post injection.
The intensity of GammaPark™ directly correlates with an increase of LID.

The right dose of Amantadine lowers GammaPark™ while stopping BetaPark at the same time.

Why SynapCell for your Parkinson’s Programs?